Technology | May 15, 2013

Vascular Solutions Announces Re-Launch of Venture Catheter

Catheter previously offered by St. Jude Medical is once again available

May 15, 2013 — Vascular Solutions Inc. announced that it has re-launched the Venture catheter, a deflectable-tip catheter used to provide guidewire directional control in challenging coronary and peripheral interventional procedures. The device is available immediately in the United States and expected to become available in select international markets over the next few months.

The Venture catheter's deflectable atraumatic distal tip can be angled up to 90 degrees, providing physicians with control and precision while navigating complex turns in the vessel and lending back-up support when crossing tight lesions. The Venture catheter is available in three versions: rapid-exchange (RX) and over-the-wire (OTW) models for difficult coronary and peripheral cases and a specialized coronary sinus version for directing wires in left-ventricular lead placement in bi-ventricular implantable defibrillator procedures. All three versions are 6 French guide-compatible and are used with standard 0.014-inch guidewires.

As previously announced, Vascular Solutions acquired the Venture catheter from St. Jude Medical Inc. in August of 2012. Since the acquisition, Vascular Solutions sold the remaining limited inventory and completed the installation and validation of the Venture production equipment and processes in its manufacturing facility. While the catheter was in full commercialization under St. Jude Medical, the Venture catheter was generating $3 million in annual worldwide sales, including approximately $2 million in U.S. sales. Vascular Solutions intends to rebuild sales gradually to those levels, with the expected sales ramp already incorporated into the company's financial guidance for 2013.

"During more than seven years on the market, the Venture catheter has amassed a very impressive record of clinical utility in some of the most challenging interventional cases," said Howard Root, chief executive officer of Vascular Solutions. "The Venture catheter is an indispensible tool for physicians who perform complex interventions, and we are very pleased to once again make this catheter available. We believe the clinical community will welcome the return of the Venture catheter to the market as we see a significant amount of initial pent-up demand for this one-of-a-kind device."

"The acquisition of the Venture catheter is consistent with our strategy of pursuing tuck-in acquisitions that leverage our existing distribution network and established call points," Root added. "The addition of the Venture catheter also is part of our commitment to offering clinical solutions in complex interventions, such as we have done with our internally-developed GuideLiner guide extension device and SuperCross microcatheters."

The Venture catheter is indicated for directing, steering, controlling and supporting a guidewire to access discrete regions of the coronary and peripheral vasculature. The over-the-wire versions may also be used for manual delivery of saline solution or diagnostic contrast agents.

For more information:

Related Content

Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
Societies Issue New Performance and Quality Measures for Treating Patients with Heart Attack
News | Cath Lab| October 17, 2017
The American College of Cardiology and the American Heart Association recently released updated clinical performance...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
Videos | Chronic Total Occlusion (CTO)| October 09, 2017
Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington, discusses the
BTG Acquires Roxwood Medical
News | Business| October 05, 2017
BTG plc announced it has acquired Roxwood Medical, provider of advanced cardiovascular specialty catheters used in the...
TVA Medical Receives CE Mark for Next-Generation EverlinQ 4 EndoAVF System
News | Vascular Access| October 04, 2017
TVA Medical Inc. announced that its everlinQ 4 endoAVF System has received CE Mark in the European Union. The...
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters| October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
TherOx Gains FDA PMA Approval for SSO2 Therapy System
Technology | Cath Lab| September 29, 2017
September 29, 2017 — TherOx Inc. announced that the U.S.
Avinger Receives CE Mark for In-Stent Restenosis Indication With Pantheris Image-Guided Atherectomy
Technology | Atherectomy Devices| September 29, 2017
Avinger Inc. recently announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis with the...
Overlay Init